DarwinHealth Recognized and Honored as One of the Top 10 Most Innovative Biotech Companies: Named to Fast Company's Prestigious Annual List of the World's Most Innovative Companies of 2025
"We deploy unique algorithmic (VIPER) and experimental (Patient-to-Model-to-Patient, PMP) technologies that can precisely identify a recurrent, druggable molecular architecture comprised of tumor checkpoints," explained DarwinHealth's CSO Mariano Alvarez who co-developed the foundational algorithm that undergirds the company's research engine. "VIPER is an algorithm based on artificial intelligence that assesses protein activity, a critical step in discovering novel cancer targets and elucidating drug mechanism-of-action."
To rank honorees from among thousands of submissions, and using the benchmarks of excellence, forward-thinking, and creativity as its vetting polestar, Fast Company's editors and writers reviewed companies driving progress around the world through a highly competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world. On March 18, 2025 , DarwinHealth joined the ranks of such biotech companies as Flagship Pioneering, Insilico Medicine, and Exscientia, previously recognized in the Fast Company competition for leveraging AI in pursuit of developing precision-based therapies for multiple disease states, including cancer.
"Our widely published innovations and clinical trials focus on the massive unmet need for cancer patients who have been unresponsive to standard-of-care, guideline-directed therapy, with the objective of extending quality survival in patients in whom other therapies have failed," explains CEO and co-founder Gideon Bosker , MD. "Because of the aforementioned innovations, which have been validated in top-tier scientific and medical journals, DarwinHealth's clinical grade technology is now being used in hundreds of cancer patients in U.S. and Europe , powering multiple clinical trials in rare and treatment-orphan malignancies, including renal, pancreatic, neuroendocrine, prostate, and brain cancer."
DarwinHealth's recognition and emergence as one of Fast Company's Most Innovative Companies (MIC) in the biotech sector is based primarily on creating innovative bioplatforms and translational through lines that merge AI/computational rigor with wet lab validations and, ultimately, peer-reviewed publications demonstrating confirmation in clinical settings. Writing in the March 18, 2025 online posting of the Fast Company MIC list, Adam Bluestein notes the 10 companies recognized in the biotech sector "are changing how we discover new drugs and treat complex diseases," adding that DarwinHealth "uses AI—its VIPER algorithm—to take experimentally measurable data from a patient's tumor, such as gene expression profiles, and make predictions about which existing drugs are most likely to be effective against the 'Tumor CheckPoint' proteins driving their particular type of cancer . . . Trial results published in 2024 showed 100% accuracy of the DarwinOncoTarget tool at predicting response to drugs called HDAC6 inhibitors in breast cancer, and a 91% accuracy of DarwinOncoTreat at predicting response of multiple tumor types."
"Along with our academic and biopharma partners, DarwinHealth is addressing the expanding unmet need for data-driven drug and target discovery using novel AI algorithms combined with experimental data and validations," explained DarwinHealth co-founder Andrea Califano , whose Lab at Columbia University developed the core technology, and who is currently President of the CHAN ZUCKERBERG BioHub ( New York ). "AI algorithms at DarwinHealth that rely on super-computing horsepower, reverse-engineering of regulatory networks for cancer and other disease states such as diabetes, viral infections, immune disorder, and degenerative brain disease are driving the development of novel bioplatforms with extraordinary predictive powers in the context of drug development."
"Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future," said Fast Company editor-in-chief Brendan Vaughan . "This year, we recognize companies that are harnessing AI in deep and meaningful ways . . . and that are introducing bold ideas . . . At a time when the world is rapidly shifting, these companies are charting the way forward."
About DarwinHealth
DarwinHealth: Precision Therapeutics for Cancer Medicine is a clinical grade, "frontiers of cancer," biotechnology-focused company, co-founded by CEO Gideon Bosker , MD, and Professor Andrea Califano , Professor of Chemical Systems Biology at Columbia University , and President, CHAN ZUCKERBERG BioHub, New York . The company's technology was developed by the Califano lab over the past 15 years and is exclusively licensed from Columbia University.
DarwinHealth utilizes proprietary, systems biology algorithms to match virtually every cancer patient with the drugs and drug combinations that are most likely to produce a successful treatment outcome. "Conversely, these same algorithms also can prioritize investigational drugs and compound combinations of unknown potential against a full spectrum of human malignancies, as well as novel cancer targets," explained Dr. Bosker, "which make them invaluable for pharmaceutical companies seeking to both optimize their compound pipelines and discover mechanistically actionable, novel cancer targets and compound-tumor alignments."
DarwinHealth's mission statement is to deploy novel technologies rooted in AI and systems biology to improve clinical outcomes of cancer treatment and other disease states. Its core technology, the VIPER algorithm, can identify tightly knit modules of master regulator proteins that represent a new class of actionable therapeutic targets in cancer. The methodology is applied along two complementary axes: First, DarwinHealth's technologies support the systematic identification and validation of druggable targets at a more foundational, deep state of the cancer cell's regulatory logic so we and our scientific partners can exploit next generation actionability based on more universal tumor dependencies and mechanisms. Second, from a drug development and discovery perspective, the same technologies are capable of identifying potentially druggable novel targets based on master regulators, and upstream modulators of those targets. This "oncotectural" approach, with its emphasis on elucidating and targeting tumor checkpoints, provides novel solutions, mechanistic validations, and positioning roadmaps for advancing precision-focused cancer drug discovery and therapeutics.
For more information, please visit: www.DarwinHealth.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias Français
AUSTIN, Texas, July 21, 2025 /CNW/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart's contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI. "This technology marks a significant advancement in how we care for patients with heart rhythm disorders—particularly those who previously had few viable cardiac resynchronization therapy treatment options," said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI. "At the Texas Cardiac Arrhythmia Institute, our commitment is to bring the most advanced, evidence-based therapies to patients worldwide, and as a result of Dr. Canby's leadership, we successfully delivered on that promise." The system is the first-ever to stimulate the heart muscle electrically via a small, leadless device—about the size of a grain of rice—that is implanted inside tissue of the left ventricle, the heart's primary pumping chamber. The device converts ultrasound energy into electrical pulses, restoring the heart's normal rhythm and pumping efficiency. Traditional cardiac resynchronization therapies involve leads—thin and soft insulated wires about the size of a spaghetti noodle. This left ventricular endocardial pacing device provides a direct approach, which enables more flexible placement and expands access to those who were previously considered untreatable. TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of esteemed cardiac electrophysiologists—led by Dr. Natale, a world-renowned expert in the field—perform a high volume of the most complex electrophysiology procedures.
Cision Canada
an hour ago
- Cision Canada
Skip and Dollarama Partner to Deliver Unmatched Convenience and Value to Canadians Français
Essentials, surprises and everything in between: Canadians can now uncover the best of Dollarama on Skip, because the real fun is in the find TORONTO, July 21, 2025 /CNW/ - Skip, Canada's homegrown delivery network, and Dollarama are coming together to highlight what value and convenience truly mean to consumers across the country, amid growing economic pressures. Starting today, Canadians can shop Dollarama's wide selection of affordable essentials and unexpected treasures, from everyday goods to seasonal must-haves and pantry staples, all delivered straight to your doorstop. This partnership brings together two iconic Canadian brands with Dollarama's unbeatable product offering and Skip's fast, reliable delivery, making everyday convenience more accessible than ever. Just in time for peak Canadian summer, the thrill of uncovering unexpected Dollarama gems is now more convenient than ever. From backyard barbecues and birthday parties, baby showers and camp prep, to the early back-to-school scrambles, the two beloved Canadian brands are joining forces to make scoring a deal easier and more exciting than ever. Together, they're bringing Canadians fast, budget-friendly access to a wide range of must haves, wherever and whenever they need them. "Finding the sweet spot between convenience and value isn't always easy, and it's often a daily challenge for Canadians," says Paul Sudarsan, SVP, Partnerships at Skip. "By bringing Dollarama to Skip, we're eliminating that compromise. This partnership strengthens Skip's role as the go-to destination for convenience and value, helping Canadians get what they need, when they need it." This launch is a major milestone for both brands, expanding Skip's retail footprint with over 1,300 Dollarama locations now live on the network across all provinces and territories where Skip operates. The coming together of Skip and Dollarama also underscores the shared mission of both companies: to deliver trusted, affordable convenience to Canadians. With Dollarama's unmatched product variety, Skip customers now have on-demand access to everything from home organization items to last-minute gifts, home goods and more! This partnership marks another exciting milestone in Skip's ongoing retail expansion, with more national retail partnerships slated to launch throughout the summer, fall and beyond. About Skip Skip is Canada's homegrown delivery network. What started in 2012 as a local start-up in the Prairies has grown into a Canadian technology success story, connecting millions of Canadians in over 450 cities and towns with more than 50,000 local restaurant, grocery, convenience and retail partners. With a vision to empower everyday convenience, Skip helps Canadians get what they need, when they need it – so they can Skip to the Good Part of their day. As a subsidiary of Just Eat one of the world's leading on-demand delivery companies, Skip combines local expertise with global scale to provide fast, reliable service when it matters most.
Cision Canada
an hour ago
- Cision Canada
Scotia Global Asset Management announces July 2025 cash distributions for Scotia ETFs Français
TORONTO, July 21, 2025 /CNW/ - Scotia Global Asset Management announced today the July 2025 cash distributions for the Scotia ETFs listed on the Cboe Canada exchange, which pay on a monthly basis. Unitholders of record on July 28, 2025 will receive a cash distribution payable on August 5, 2025, as noted below. For more information on the Scotia ETFs, please visit the Scotia Exchange Traded Funds (ETF) website. Commissions, trailing commissions, management fees and expenses may be associated with mutual fund investments, including exchange-traded funds (ETFs). Please read the prospectus before investing. Mutual funds and ETFs are not guaranteed, their values change frequently and past performance may not be repeated. About Scotia Global Asset Management Scotia Global Asset Management® is a business name used by 1832 Asset Management L.P., a limited partnership, the general partner of which is wholly owned by Scotiabank. Scotia Global Asset Management offers a range of wealth management solutions, including mutual funds, ETFs, liquid alternative mutual funds, private asset funds and customized investment solutions for institutions and managed asset programs. For more information, please visit About Scotiabank Scotiabank's vision is to be our clients' most trusted financial partner and deliver sustainable, profitable growth. Guided by our purpose: "for every future," we help our clients, their families and their communities achieve success through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With assets of approximately $1.4 trillion (as at April 30, 2025), Scotiabank is one of the largest banks in North America by assets, and trades on the Toronto Stock Exchange (TSX: BNS) and New York Stock Exchange (NYSE: BNS). For more information, please visit and follow us on X @Scotiabank.
